Immunome Inc. (IMNM)
Data as of , from SEC Form 4 filings.
See up to 3 months of IMNM. The 7-day demo opens the 1M and 3M ranges and puts IMNM on your watchlist.
Start 7-day demoLatest IMNM insider trades
Jack Higgins - OfficerOpen-market sale$334K- Isaac Barchas - DirectorOpen-market sale
About Immunome Inc. (IMNM)
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
- BOTHELL, WA
- 177
- 2020
- XNAS
IMNM Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 7 | 223,368 | $5.75M |
| Grant or award | 14 | 1,281,750 | |
| Option exercise | 6 | 217,232 | |
IMNM insider transactions (Form 4)
7145 Form 4 filings on record, the earliest from Nov 25, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jack Higgins - Officer | Option exercise | Common Stock | 18,000 | $1.35 | $24K | |
| Jack Higgins - Officer | Open-market sale | Common Stock | 13,200 | $25.32 | $334K | |
| Jack Higgins - Officer | Gift | Common Stock | 8,800 | $0.00 | - | |
| Jack Higgins - Officer | Option exercise | Employee Stock Option (right to buy) | 18,000 | $0.00 | - | |
| Isaac Barchas - Director | Open-market sale | Common Stock | 10,125 | $26.07 footnote F2 | $264K | |
| Isaac Barchas - Director | Open-market sale | Common Stock | 62,291 | $26.23 footnote F4 | $1.63M | |
| Isaac Barchas - Director | Open-market sale | Common Stock | 11,048 | $27.25 | $301K | |
| ||||||
| Isaac Barchas - Director | Open-market sale | Common Stock | 20,840 | $26.06 footnote F2 | $543K | |
| Isaac Barchas - Director | Open-market sale | Common Stock | 15,248 | $26.06 footnote F4 | $397K | |
| ||||||
| Kinney Horn - Officer | Option exercise | Common Stock | 50,366 | $12.92 | $651K | |
| Kinney Horn - Officer | Option exercise | Common Stock | 40,250 | $10.60 | $427K | |
| Kinney Horn - Officer | Open-market sale | Common Stock | 90,616 | $25.09 footnote F2 | $2.27M | |
| Kinney Horn - Officer | Option exercise | Employee Stock Option (right to buy) | 50,366 | $0.00 | - | |
| Kinney Horn - Officer | Option exercise | Employee Stock Option (right to buy) | 40,250 | $0.00 | - | |
| ||||||
| Kinney Horn - Officer | Grant or award | Common Stock | 31,250 footnote F1 | $0.00 | - | |
| Kinney Horn - Officer | Grant or award | Employee Stock Option (right to buy) | 62,500 | $0.00 | - | |
| ||||||
| Philip Tsai - Officer | Grant or award | Common Stock | 38,250 footnote F1 | $0.00 | - | |
| Philip Tsai - Officer | Grant or award | Employee Stock Option (right to buy) | 76,500 | $0.00 | - | |
| ||||||
 Sandra G. Stoneman - Officer | Grant or award | Common Stock | 38,250 footnote F1 | $0.00 | - | |
| Sandra G. Stoneman - Officer | Grant or award | Employee Stock Option (right to buy) | 76,500 | $0.00 | - | |
| ||||||
| Jack Higgins - Officer | Grant or award | Common Stock | 38,250 footnote F1 | $0.00 | - | |
| Jack Higgins - Officer | Grant or award | Employee Stock Option (right to buy) | 76,500 | $0.00 | - | |
| ||||||
 Max Rosett - Officer | Grant or award | Common Stock | 47,250 footnote F1 | $0.00 | - | |
| Max Rosett - Officer | Grant or award | Employee Stock Option (right to buy) | 94,500 | $0.00 | - | |
| ||||||
 Robert Lechleider - Officer | Grant or award | Common Stock | 54,000 footnote F1 | $0.00 | - | |
| Robert Lechleider - Officer | Grant or award | Employee Stock Option (right to buy) | 108,000 | $0.00 | - | |
| ||||||
 Clay B. Siegall - Officer | Grant or award | Common Stock | 180,000 footnote F1 | $0.00 | - | |
| Clay B. Siegall - Officer | Grant or award | Employee Stock Option (right to buy) | 360,000 | $0.00 | - | |
| ||||||
| Kinney Horn - Officer | Option exercise | Common Stock | 1,092 | $12.92 | $14K | |
| Kinney Horn - Officer | Open-market sale | Common Stock | 1,092 | $25.00 | $27K | |
| Kinney Horn - Officer | Option exercise | Employee Stock Option (right to buy) | 1,092 | $0.00 | - | |
| Isaac Barchas | Open-market sale | Common Stock | 83,094 | $24.11 footnote F2 | $2.00M | |
| Isaac Barchas | Open-market sale | Common Stock | 16,906 | $24.20 footnote F4 | $409K | |
| ||||||
| Robert Lechleider - Officer | Option exercise | Common Stock | 55,000 | $8.73 | $480K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 22,714 | $21.95 footnote F2 | $499K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 16,214 | $22.76 footnote F3 | $369K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 16,072 | $23.44 footnote F4 | $377K | |
| Robert Lechleider - Officer | Option exercise | Employee Stock Option (right to buy) | 55,000 | $0.00 | - | |
| ||||||
| Isaac Barchas | Open-market sale | Common Stock | 101,050 footnote F2 | $21.12 footnote F3 | $2.13M | |
| Isaac Barchas | Open-market sale | Common Stock | 75,665 | $22.35 footnote F6 | $1.69M | |
| Isaac Barchas | Open-market sale | Common Stock | 24,335 | $23.33 footnote F8 | $568K | |
| ||||||
| Robert Lechleider - Officer | Option exercise | Common Stock | 55,000 | $8.73 | $480K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 40,580 | $19.56 footnote F2 | $794K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 14,420 | $20.66 footnote F3 | $298K | |
| Robert Lechleider - Officer | Option exercise | Employee Stock Option (right to buy) | 55,000 | $0.00 | - | |
| ||||||
| Max Rosett - Officer | Option exercise | Common Stock | 60,000 | $1.05 | $63K | |
| Max Rosett - Officer | Open-market sale | Common Stock | 60,000 | $18.23 footnote F2 | $1.09M | |
| Max Rosett - Officer | Option exercise | Stock Option (right to buy) | 60,000 | $0.00 | - | |
| ||||||
| Sandra M. Swain | Grant or award | Director Stock Option (right to buy)` | 9,897 | $0.00 | - | |
| Philip Wagenheim | Grant or award | Director Stock Option (right to buy) | 9,897 | $0.00 | - | |
| Jean Jacques Bienaime | Grant or award | Director Stock Option (right to buy) | 9,897 | $0.00 | - | |
| James P. Boylan | Grant or award | Director Stock Option (right to buy) | 9,897 footnote F1 | $0.00 | - | |
| ||||||
| Isaac Barchas | Grant or award | Director Stock Option (right to buy) | 9,897 footnote F1 | $0.00 | - | |
| ||||||
| Carol Schafer | Grant or award | Director Stock Option (right to buy) | 9,897 | $0.00 | - | |
| Jean Jacques Bienaime | Open-market sale | Common Stock | 500 | $19.44 | $10K | |
| Jean Jacques Bienaime | Open-market sale | Common Stock | 10,000 | $19.41 | $194K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 6,000 | $19.48 | $117K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 3,500 | $19.46 | $68K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 1,000 | $19.27 | $19K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 5,000 | $20.70 footnote F1 | $104K | |
| ||||||
| Jack Higgins - Officer | Open-market sale | Common Stock | 9,438 | $21.64 | $204K | |
| Max Rosett - Officer | Option exercise | Common Stock | 31,848 | $1.05 | $33K | |
| Max Rosett - Officer | Option exercise | Common Stock | 39,713 | $1.35 | $54K | |
| Max Rosett - Officer | Open-market sale | Common Stock | 63,656 | $21.91 footnote F2 | $1.39M | |
| Max Rosett - Officer | Open-market sale | Common Stock | 1,344 | $22.48 footnote F3 | $30K | |
| Max Rosett - Officer | Option exercise | Stock option (right to buy) | 31,848 | $0.00 | - | |
| Max Rosett - Officer | Option exercise | Stock option (right to buy) | 39,713 | $0.00 | - | |
| ||||||
| Jack Higgins - Officer | Gift | Common Stock | 6,291 | $0.00 | - | |
| Clay B. Siegall - Officer | Open-market purchase | Common Stock | 25,450 | $19.67 footnote F1 | $501K | |
| ||||||
| Philip Wagenheim | Open-market sale | Common Stock | 36,800 | $20.47 footnote F1 | $753K | |
| Philip Wagenheim | Open-market sale | Common Stock | 28,200 | $20.65 footnote F2 | $582K | |
| ||||||
Item 1.01, 3.02, 9.01
Item 2.02, 9.01
Item 5.07
Item 2.02, 9.01
Recent IMNM Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Higgins Jack | Officer | 13,200 | $334K | View on EDGAR | |
| Barchas Isaac | Director | 11,048 | $301K |
IMNM insider trading FAQ
What is the latest insider trade for IMNM?
Immunome Inc. (IMNM) had 11 insider filings in the last 90 days, with the most recent on 2026-09-15. The full record for IMNM runs to 45 Form 4 filings, the earliest from 2024-11-25. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying IMNM stock?
No insider purchases of IMNM were filed in the last 90 days. 12 purchases are on record for this company.
How many insiders are selling IMNM stock?
7 insider sales of IMNM were filed in the last 90 days, totaling $5.75M.
Where can I see IMNM SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects IMNM Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jack Higgins view on EDGAR
- - Isaac Barchas view on EDGAR
- - Isaac Barchas view on EDGAR
- - Kinney Horn view on EDGAR
- - Kinney Horn view on EDGAR
- - Philip Tsai view on EDGAR
- - Sandra G. Stoneman view on EDGAR
- - Jack Higgins view on EDGAR
- - Max Rosett view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where IMNM's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow IMNM with a 7-day demo
- IMNM on your watchlist
- Every IMNM Form 4 filing on record
- Up to 3 months of IMNM price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
